Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;85(5):1274-1284.
doi: 10.1016/j.jaad.2021.07.054. Epub 2021 Aug 4.

COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence

Sarah Wack  1 , Timothy Patton  1 , Laura K Ferris  2
Affiliations
Review

COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence

Sarah Wack et al. J Am Acad Dermatol. 2021 Nov.

Abstract

Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID). Understanding the inherent immune dysregulation of these diseases as well as the additional disruption that comes as a result of IMID treatments has been important during the COVID-19 pandemic. With vaccines becoming widely available, dermatologists need to be familiar with the risks and benefits of vaccination in these patients, particularly those taking biologics, in order to have informed discussions with their patients. In this review, we present the current evidence related to COVID-19 vaccine safety and efficacy in patients with IMID and review existing recommendations for vaccination against SARS-CoV-2. Given the current evidence, there is minimal concern that these patients are at any greater risk of harm from COVID-19 vaccination compared to healthy controls. For most, the benefit of avoiding severe COVID-19 through vaccination will outweigh the theoretical risk of these vaccines. A question that is still outstanding is whether patients on biologics will generate a sufficient immune response to the vaccine, which may be dependent on the specific biologic therapy and indication being treated. This underscores the importance of following patients with IMID after vaccination to determine the safety, efficacy, and duration of the vaccine in this population.

Keywords: COVID-19; IMID; MCTD; SARS-CoV-2; Systemic Lupus Erythematosus; atopic dermatitis; autoimmune disease; autoimmunity; biologics; dermatomyositis; hidradenitis suppurativa; myositis; pemphigoid; pemphigus; psoriasis; sarcoid; sclerosis; vaccines; vasculitis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Ferris is an investigator for Amgen, UBC, AbbVie, Regeneron, Eli Lilly, BI, Janssen, Galderma, Arcutis, Dermavant, Novartis, and BMS and a consultant for AbbVie, Eli Lilly, Janssen, Arcutis, Dermavant, BMS, Sun Pharma, and Pfizer. Dr Patton is an investigator for Amgen, UBC, AbbVie, Regeneron, Eli Lilly, BI, Janssen, Galderma, Arcutis, Dermavant, Novartis, and BMS. Author Wack has no conflicts of interest to declare.

References

    1. Zhang J., Xie F., Delzell E., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–49. doi: 10.1001/jama.2012.7304. - DOI - PMC - PubMed
    1. Croce E., Hatz C., Jonker E.F., Visser L.G., Jaeger V.K., Bühler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation: a systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;35(9):1216–1226. doi: 10.1016/j.vaccine.2017.01.048. - DOI - PubMed
    1. Heaton P.M. The Covid-19 vaccine-development multiverse. N Engl J Med. 2020;383(20):1986–1988. doi: 10.1056/NEJMe2025111. - DOI - PMC - PubMed
    1. U.S. Food & Drug Administration COVID-19 vaccine emergency use authorization letter of authorization. Moderna. 2021. https://www.fda.gov/media/144636/download
    1. U.S. Food & Drug Administration BioNTech COVID-19 Vaccine Emergency Use Authorization Letter of Authorization. Pfizer, Inc. 2021. https://www.fda.gov/media/144412/download

MeSH terms